Trial Profile
Evaluation of Polymorphisms and Mutations in Genes Postulated to Alter the Efficacy of Gefitinib in Samples From E1302
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary) ; Docetaxel
- Indications Head and neck cancer
- Focus Biomarker; Pharmacodynamics